Correlation of OCT characteristics and retinal sensitivity in neovascular age-related macular degeneration in the course of monthly ranibizumab treatment

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 2, 2013, Pages 1310-1315

  Sulzbacher, Florian ^a   Kiss, Christopher ^a   Kaider, Alexandra ^a   Roberts, Philipp ^a   Munk, Marion ^a   Kroh, Maria Elisabeth ^a   Sayegh, Ramzi ^a   Schmidt Erfurth, Ursula ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CLINICAL ARTICLE; EXUDATIVE MACULAR DEGENERATION; HUMAN; IMAGE ANALYSIS; MALE; OPHTHALMOSCOPY; PERIMETRY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; SLIT LAMP; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETINAL NEOVASCULARIZATION; RETINAL PIGMENT EPITHELIUM; SENSORY THRESHOLDS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FIELD TESTS;

EID: 84874954229     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11046     Document Type: Article

References (21)

1. Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003;136:407-418.
2. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: three-year results from randomized clinical trials. Arch Ophthalmol. 1986;104:694-701.
3. Paulaikhoff D. Neovascular age-related macular degeneration: natural history and treatment outcomes. Retina. 2005;25: 1065-1084.
4. Schmidt-Erfurth U, Richard G, Augustin A, et al. Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand. 2007;85:486-494.
5. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
6. Martin DF, Maguire MG, Fine SL, et al. Ranbizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-1908.
7. Rosenfeld PJ, Shapiro H, Tuomi L, et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology. 2011; 118:523-530.
8. Sulzbacher F, Kiss C, Kaider A, et al. Correlation of SD-OCT features and retinal sensitivity in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2012;53: 6448-6455.
9. Boyer DS, Abtoszyk A, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:246-252.
10. Brown DM, Michels M, Kaiser PK, et al.; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two year results of the ANCHOR study. Ophthalmology. 2009;116:57-65.
11. Charbel Issa P, Troeger E, Finger R, et al. Structure-function correlation of the human central retina. PloS One. 2010;22: e12864.
12. Landa G, Su E, Garcia P, et al. Inner segment-outer segment junctional layer integrity and corresponding retinal sensitivity in dry and wet forms of age-related macular degeneration. Retina. 2011;31:364-370.
13. Kiss CG, Geitzenauer W, Simader C, et al. Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function. Invest Ophthalmol Vis Sci. 2009;50:2376-2383.
14. Hayashi H, Yamashiro K, Tsujikawa A, et al. Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration. Am J Ophthalmol. 2009;148:83-89.
15. Oishi A, Hata M, Shimozono M, et al. The significance of external limiting membrane status for visual acuity in agerelated macular degeneration. Am J Ophthalmol. 2010;150: 27-32. e1.
16. Gamulescu MA, Panagakis G, Theek C, et al. Predictive factors in OCT analysis for visual outcome in exudative AMD [published online ahead of print March 19, 2012]. J Ophthalmol. doi:10.1155/2012/851648.
17. Kim YM, Kim JH, Koh HJ. Improvement of photoreceptor integrity and associated visual outcome in neovascular agerelated macular degeneration. Am J Ophthalmol. 2012;154: 164-173. e1.
18. Mariani A, Deli A, Ambresin A, Mantel I. Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2011;249:1635-1642.
19. Chan CK, Abraham P, Meyer CH, et al. Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. Retina. 2010;30: 203-211.
20. Pauleikhoff D, L̈offert D, Spital G, et al. Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol. 2002;240:533-538.
21. Freeman WR, Kozak I, Yuson RM, et al. Prognostic implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization. Retina. 2011;31:1812-1818.